Viral vector development CDMO, Matica Biotechnology Inc, has signed a Letter of Intent to allow U.S.-based biotech, KaliVir Immunotherapeutics, to develop advanced cancer therapies using Matica Bio’s Vaccinia Enhanced Template (VET™) platform.

The collaboration aims to accelerate the development of KaliVir's oncolytic virus therapies by focusing on a new manufacturing process using Matica Bio’s proprietary MatiMax™ cell line for the process.

The following article originally appeared in BusinessWire.

Matica Biotechnology Inc. (Matica Bio), a CDMO specializing in viral vector development and manufacturing, announced the signing of a Letter of Intent (LOI) with KaliVir Immunotherapeutics, a U.S.-based clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapies.

KaliVir is at the forefront of developing novel cancer therapies using its proprietary Vaccinia Enhanced Template (VET™) platform. This platform allows for the expression and systemic delivery of multiple therapeutic transgenes. KaliVir’s lead clinical candidate, VET3-TGI, expresses interleukin-12 and a TGFbeta inhibitor.

Under this new partnership, Matica Bio will utilize its proprietary cell line, MatiMax™, to explore a new manufacturing process for KaliVir’s oncolytic virus product.

Helena Chaye, CEO of KaliVir, stated, “Our collaboration with Matica Bio allows us to accelerate the development of our oncolytic virus therapies. This agreement is expected to expand our strategic partnership across all phases of product development.”

“The development of production processes for viral vectors is crucial for the stable production of high-quality therapeutics. Through this agreement, we aim to leverage our high-performance MatiMax™ cell line and CGT manufacturing expertise to actively support KaliVir’s oncolytic virus program,” said Paul Kim, CEO of Matica Bio.

Matica Biotechnology has viral vector facilities in College Station, Texas, purpose-built and equipped with single-use system to develop and produce viral vectors, a key raw material for cell and gene therapies. In June 2023, Matica successfully developed its proprietary MatiMax™ cell line, enhancing viral vector production efficiency. The company continues to expand its contract service orders while advancing biomanufacturing technologies.

For more, please find the original story source here.